tadalafil has been researched along with Priapism in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Abbasi, B; Breyer, BN; Hakam, N; Lui, JL; Shaw, NM | 1 |
| Gross, MS; Rezaee, ME | 1 |
| Cabrini, MR; Nardozza, A | 1 |
| Carrieri, G; Cormio, L; D'Altilia, N; Massenio, P; Sanguedolce, F | 1 |
| Gaillard, R; Loulergue, P; Mir, O | 1 |
| Fioravanti, A; Galatti, L; Giustini, SE; Polimeni, G; Salvo, F | 1 |
| Hallock, M; King, SH; Strote, J; Wessells, H | 1 |
| Bivalacqua, TJ; Burnett, AL; Champion, HC; Musicki, B | 1 |
| Gustafsson, LE; Hallén, K; Wiklund, NP | 1 |
1 review(s) available for tadalafil and Priapism
| Article | Year |
|---|---|
Are We Overstating the Risk of Priapism With Oral Phosphodiesterase Type 5 Inhibitors?
Topics: Erectile Dysfunction; Humans; Male; Phosphodiesterase 5 Inhibitors; Priapism; Sildenafil Citrate; Tadalafil | 2020 |
8 other study(ies) available for tadalafil and Priapism
| Article | Year |
|---|---|
Adverse reactions of PDE5 inhibitors: An analysis of the World Health Organization pharmacovigilance database.
Topics: Adolescent; Adult; Erectile Dysfunction; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Pharmacovigilance; Phosphodiesterase 5 Inhibitors; Priapism; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride; World Health Organization | 2023 |
Daily use of phosphodiesterase type 5 inhibitors as prevention for recurrent priapism.
Topics: Adult; Cyclic Nucleotide Phosphodiesterases, Type 5; Follow-Up Studies; Humans; Male; Phosphodiesterase 5 Inhibitors; Priapism; Prospective Studies; Recurrence; Secondary Prevention; Tadalafil; Young Adult | 2017 |
Daily tadalafil for the chronic phase of stuttering priapism: a case report.
Topics: Drug Administration Schedule; Follow-Up Studies; Humans; Male; Priapism; Tadalafil; Vasodilator Agents; Young Adult | 2018 |
Interaction involving tadalafil and CYP3A4 inhibition by ritonavir.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbolines; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; HIV Infections; Humans; Male; Priapism; Ritonavir; Tadalafil | 2011 |
Interaction between tadalafil and itraconazole.
Topics: Antifungal Agents; Carbolines; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Humans; Itraconazole; Male; Middle Aged; Phosphodiesterase Inhibitors; Priapism; Tadalafil | 2005 |
Tadalafil-associated priapism.
Topics: Adult; Carbolines; Erectile Dysfunction; Humans; Male; Phosphodiesterase Inhibitors; Priapism; Tadalafil | 2005 |
Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adult; Anemia, Sickle Cell; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Male; Nitric Oxide; Penile Erection; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Priapism; Purines; Recurrence; Signal Transduction; Sildenafil Citrate; Sulfones; Tadalafil | 2006 |
Inhibitors of phosphodiesterase 5 (PDE 5) inhibit the nerve-induced release of nitric oxide from the rabbit corpus cavernosum.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Carbolines; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Imidazoles; In Vitro Techniques; Male; Muscle, Smooth; Nitrergic Neurons; Nitric Oxide; Penis; Phosphodiesterase Inhibitors; Piperazines; Priapism; Purines; Rabbits; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2007 |